TABLE 3.

Characteristics of CUD patients with depression receiving ketamine treatment or other antidepressant treatment before and after propensity score-matching.

Characteristics	Before matching			After matching
	Ketamine cohort	Antidepressant cohort	SMD	Ketamine cohort	Antidepressant cohort	SMD
Total no.	3959	65 680		3955	3955
Age, mean (SD)	42.5 (13.2)	42.6 (14.3)	0.003	42.5 (13.2)	43.1 (14.1)	0.04
Sex, %
Female	43.7	45.4	0.03	43.6	43.2	0.009
Male	56.3	54.6	0.04	56.4	56.7	0.008
Ethnicity, %
Hispanic/Latinx	8.7	6.8	0.07	8.6	7.9	0.02
Not Hispanic/ Latinx	76.1	72.7	0.08	76.1	78.3	0.05
Race, %
African American/Black	25.8	32.1	0.14	25.8	26.2	0.007
White	60.2	56.1	0.08	60.2	60.7	0.01
Asian	0.5	0.6	0.02	0.5	0.4	0.01
Comorbidities, %
Mental and behavioral disorders	90.6	81.5	0.26	90.6	90.8	0.006
Mood disorders	76.2	71%	0.12	76.2	77.2	0.02
Anxiety	62.3	49.1	0.27	62.3	61.7	0.01
Schizophrenia	18.3	16.1	0.06	18.3	16.4	0.05
Hypertensive diseases	45.8	35.5	0.21	45.8	47.9	0.04
Ischemic heart diseases	21.7	12.8	0.24	21.6	22.2	0.01
Other forms of heart disease	46.1	24.1	0.47	46.1	47.8	0.04
Cerebrovascular diseases	16.9	9.1	0.23	16.7	16.6	0.004
Acute kidney failure	23.3	10.1	0.36	23.2	22.6	0.01
Antisocial personality disorder	1.5	1.3	0.01	1.5	1.1	0.04
Conduct disorder	9.9	4.6	0.21	9.8	8.5	0.04
ADHD	7.5	6.3	0.05	7.5	5.9	0.06
Socio-economic and psychosocial status	31.6	21.2	0.24	31.5	29.3	0.05

Note: Values shown in bold type are significant at SMD > 0.1.

Abbreviation: ADHD, attention-deficit/hyperactivity disorder; CUD, cocaine use disorder; SMD, standardized mean difference.